Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE:300318)
China · Delayed Price · Currency is CNY 6.25
-0.02 (-0.32%)
At close: Feb 13, 2026
SHE:300318 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 799.74 | 817.05 | 998.91 | 751.6 | 682.18 | 723.17 |
Other Revenue | 34.64 | 34.64 | 46.52 | 44.33 | 32.57 | 15.54 |
| 834.38 | 851.69 | 1,045 | 795.93 | 714.75 | 738.72 | |
Revenue Growth (YoY) | -5.76% | -18.53% | 31.35% | 11.36% | -3.25% | 17.57% |
Cost of Revenue | 496.77 | 434.16 | 593.97 | 542.42 | 422.28 | 385.56 |
Gross Profit | 337.61 | 417.53 | 451.46 | 253.51 | 292.47 | 353.16 |
Selling, General & Admin | 256.3 | 286 | 306.15 | 269.64 | 308.94 | 265.39 |
Research & Development | 49.84 | 52.52 | 69.2 | 64.78 | 81.48 | 48.18 |
Other Operating Expenses | 21.72 | 14.45 | 15.84 | 15.96 | 13.41 | 11.3 |
Operating Expenses | 330.05 | 354.68 | 392.5 | 352.67 | 404.44 | 326.96 |
Operating Income | 7.56 | 62.86 | 58.97 | -99.16 | -111.98 | 26.21 |
Interest Expense | -31.8 | -28.96 | -27.62 | -42.25 | -45.06 | -35.44 |
Interest & Investment Income | 0.64 | 1.92 | 4.78 | 0.51 | 4.97 | 5.49 |
Currency Exchange Gain (Loss) | -1.29 | -1.29 | -0.45 | -1.07 | -0.45 | -0.01 |
Other Non Operating Income (Expenses) | -22.99 | -6.42 | -8.74 | -6.79 | -3.98 | 0.82 |
EBT Excluding Unusual Items | -47.88 | 28.1 | 26.94 | -148.76 | -156.5 | -2.93 |
Impairment of Goodwill | - | - | - | -15.92 | -340.68 | -0.32 |
Gain (Loss) on Sale of Investments | -1.5 | - | - | - | - | 0.09 |
Gain (Loss) on Sale of Assets | -4.27 | 0.12 | 1.11 | 31.97 | 0.14 | 0.19 |
Asset Writedown | 0.75 | -2.55 | -3.31 | -1.61 | -20.43 | -0.16 |
Other Unusual Items | -46.2 | -5.76 | 8.98 | 0.55 | 13.29 | 3.72 |
Pretax Income | -99.1 | 19.91 | 33.73 | -133.78 | -504.18 | 0.59 |
Income Tax Expense | -1.31 | 11.23 | 18.05 | 4.39 | 1.61 | 8.14 |
Earnings From Continuing Operations | -97.78 | 8.68 | 15.68 | -138.17 | -505.79 | -7.55 |
Minority Interest in Earnings | 49.7 | 0.57 | -40.61 | 59.73 | 183.61 | 15.06 |
Net Income | -48.09 | 9.25 | -24.93 | -78.44 | -322.18 | 7.5 |
Net Income to Common | -48.09 | 9.25 | -24.93 | -78.44 | -322.18 | 7.5 |
Net Income Growth | - | - | - | - | - | 195.11% |
Shares Outstanding (Basic) | 818 | 818 | 817 | 817 | 817 | 816 |
Shares Outstanding (Diluted) | 818 | 818 | 817 | 817 | 817 | 816 |
Shares Change (YoY) | 0.05% | 0.11% | 0.03% | 0.03% | 0.15% | -0.56% |
EPS (Basic) | -0.06 | 0.01 | -0.03 | -0.10 | -0.39 | 0.01 |
EPS (Diluted) | -0.06 | 0.01 | -0.03 | -0.10 | -0.39 | 0.01 |
EPS Growth | - | - | - | - | - | 196.77% |
Free Cash Flow | -292.71 | -227.64 | -60.53 | -120.74 | -366.17 | -116.2 |
Free Cash Flow Per Share | -0.36 | -0.28 | -0.07 | -0.15 | -0.45 | -0.14 |
Gross Margin | 40.46% | 49.02% | 43.18% | 31.85% | 40.92% | 47.81% |
Operating Margin | 0.91% | 7.38% | 5.64% | -12.46% | -15.67% | 3.55% |
Profit Margin | -5.76% | 1.09% | -2.38% | -9.86% | -45.08% | 1.02% |
Free Cash Flow Margin | -35.08% | -26.73% | -5.79% | -15.17% | -51.23% | -15.73% |
EBITDA | 95.74 | 156 | 158.74 | 6.53 | -7.09 | 116.13 |
EBITDA Margin | 11.47% | 18.32% | 15.18% | 0.82% | -0.99% | 15.72% |
D&A For EBITDA | 88.18 | 93.15 | 99.77 | 105.69 | 104.89 | 89.93 |
EBIT | 7.56 | 62.86 | 58.97 | -99.16 | -111.98 | 26.21 |
EBIT Margin | 0.91% | 7.38% | 5.64% | -12.46% | -15.67% | 3.55% |
Effective Tax Rate | - | 56.41% | 53.51% | - | - | 1390.93% |
Revenue as Reported | 834.38 | 851.69 | 1,045 | 795.93 | 714.75 | 738.72 |
Advertising Expenses | - | 15.2 | 17.36 | 14.71 | 31.57 | 47.49 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.